ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September 11, 2026. The company also released its full Annual Report for the financial year 2025-26.
Vivanza Biosciences approved its annual reports, the convening of the 44th AGM, and various procedural resolutions including borrowing limits and related party transactions for upcoming periods.
Vivanza Biosciences has scheduled a board meeting for August 17, 2026, to discuss the AGM, financial reports, and various corporate authorizations under the Companies Act.
Vivanza Biosciences Ltd reported revenue from operations of ₹9.3 Cr (+4.5% YoY) and net profit of ₹0.1 Cr (+0.0% YoY) for Q1 FY27.
Vivanza Biosciences has scheduled a board meeting on August 01, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026.
Vivanza Biosciences declared that its statutory auditors issued an audit report with an unmodified opinion. This covers results for the quarter and year ended March 31, 2026.
Vivanza Biosciences appointed Mr. Vishal Sureshbhai Katarmal as Company Secretary and Compliance Officer. The Board also noted a strategic agreement for a manufacturing project in Kyrgyzstan.
Vivanza Biosciences disclosed a strategic cooperation and technology transfer agreement to explore a plastic film manufacturing project in Kyrgyz Republic. No monetary consideration is involved at present.
Vivanza Biosciences announced the Board meeting scheduled for 18 June 2026. The meeting will consider auditor appointment, director nomination and share transfer matters.
Vivanza Biosciences confirmed non-applicability of SEBI's Related Party Transaction disclosures for March 2026. The company remains below regulatory thresholds for mandatory reporting.
Vivanza Biosciences Ltd reported revenue from operations of ₹6.4 Cr (+1180.0% YoY) and a net loss of ₹0.5 Cr for Q4 FY26.
Vivanza Biosciences reported audited standalone annual revenue of ₹112.34 Crore. The Board also noted resignations of its Director and Company Secretary during the meeting.
Vivanza Biosciences Limited has rescheduled its Board Meeting to May 7, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The meeting was originally planned for May 4, 2026. The trading window will remain closed until 48 hours after the results declaration.
Mr. Chaitra Arora has resigned as Company Secretary and Compliance Officer of Vivanza Biosciences Limited, effective April 30, 2026. He is departing to pursue career opportunities outside the company. The board has acknowledged the resignation, noting no material reasons for his departure other than personal professional growth.
Vivanza Biosciences Ltd has scheduled a Board of Directors meeting on May 04, 2026. The board will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until 48 hours after the results declaration.
Vivanza Biosciences Ltd announced the non-applicability of the Annual Secretarial Compliance Report for the year ended March 31, 2026. The company is exempt under SEBI Regulation 15(2) as its paid-up capital is ₹4 Crore and net worth is approximately ₹4.02 Crore, both falling below the mandatory reporting thresholds.
Vivanza Biosciences Limited submitted a compliance filing confirming that a Statement of Deviation or Variation is not applicable. The company has not raised any fresh capital through public, rights, or preferential issues. This routine regulatory disclosure under SEBI Regulation 32 ensures transparency regarding the use of proceeds from capital raises.
Vivanza Biosciences Ltd confirmed it does not qualify as a 'Large Corporate' as of March 31, 2026, based on SEBI criteria. With zero outstanding borrowings, the company is exempt from the initial disclosure requirements for the financial year ended 2026.
Vivanza Biosciences Ltd submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The registrar, Purva Sharegistry (I) Pvt Ltd, confirmed that nil share certificates were received for dematerialisation during the quarter. This is a routine regulatory disclosure with no material financial impact.